An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 10 Feb 2018 A first interim analysis for safety is planned after 18 patients enrolled and treated (by December 1st, 2017).
- 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
- 28 Mar 2017 Trial designed were presented at the 32nd Congress of the European Association of Urology.